Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
Riccardo Menandro, Pharmaceutical Scientific Reporter at Maven Pharma, shared on LinkedIn:
”Most conversations about lipid nanoparticles focus on the science.
This one focuses on the decisions.
LNP technology has moved from research platform to clinical mainstream faster than almost any other delivery system in recent memory.
Patisiran demonstrated hepatic gene silencing at therapeutic scale.
The COVID-19 vaccines demonstrated industrial scalability.
The pipeline now spans oncology, rare disease, hemophilia, and in vivo CRISPR editing.
But for organizations building or evaluating LNP-based programs, the scientific opportunity is only part of the picture.
Formulation expertise, IP position, tissue targeting strategy, and regulatory engagement are the variables that determine whether a program reaches the clinic on a competitive timeline, or doesn’t.
This white paper examines all four, with a focus on the decisions that matter most at the development planning stage.
Full document attached.”
Stay updated with Hemostasis Today.
-
Aug 25, 2026, 07:28Manuel Monreal: VTE and Severe Renal Insufficiency – What Does RIETE Tell Us?
-
Aug 25, 2026, 07:26Tom B.: Platelet Transfusion as a Potential Mitochondrial Therapy for Sepsis
-
Aug 25, 2026, 07:20Scott McInnes: Giving Blood When the Need Is Greater Than Ever
-
Aug 25, 2026, 06:10Shiny K. Kajal: Rh Is More Than Just Positive or Negative
-
Aug 25, 2026, 00:07Muhammad Ali Khan: Using EHR Data to Predict Fibrotic Progression in PV and ET
-
Aug 25, 2026, 00:06Michael R. Scoma: The Vascular Dimension of Long COVID
-
Aug 24, 2026, 23:40Vimee Bindra: Your Period May Be Trying to Tell You Something
-
Aug 24, 2026, 23:30R. P. Singh: Hemophilia and HIV Relationship
-
Aug 24, 2026, 23:12Marta Velia Antonini: Hemolysis in ECMO – More Than Just a Laboratory Finding